The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
Information source: University Urological Associates Inc.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Prostate Cancer
Phase: N/A
Status: Not yet recruiting
Sponsored by: University Urological Associates Inc. Official(s) and/or principal investigator(s):
Steven I Cohen, MD, Principal Investigator, Affiliation: University Urological Associates Inc.
Overall contact:
Steven I Cohen, MD, Phone: 4012727799, Ext: 1232, Email: sicppmd@cox.net
Summary
This is a review of previously published data from a large prostate cancer prevention study
known as REDUCE. It is the investigators intention to review whether prostate specific
antigen (PSA) velocity (change over time) will predict the presence of prostate cancer and
its grade and stage (severity).
Clinical Details
Official title: Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
Study design: Observational Model: Case Control, Time Perspective: Retrospective
Detailed description:
This is a review of previously published data from a large prostate cancer prevention study
known as REDUCE that utilized a 5 ARI, dutasteride. It is the investigators intention to
review whether PSA velocity (change over time) will predict the presence of prostate cancer
and its grade and stage (severity) by two year biopsy. The investigator will review and
compare data to a previously published study of similar design with finasteride.
Eligibility
Minimum age: 50 Years.
Maximum age: 74 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Men,
- 50-74 years old with elevated PSA (>=4) along with negative entry biopsy of the
prostate who had a subsequent biopsy by 24 months.
Exclusion Criteria:
- Any positive biopsy of the prostate indicative of cancer upon entry
Locations and Contacts
Steven I Cohen, MD, Phone: 4012727799, Ext: 1232, Email: sicppmd@cox.net
Division of Urology, Brown University, Providence, Rhode Island 02903, United States; Not yet recruiting
Steven I Cohen, MD, Principal Investigator
Additional Information
Starting date: January 2012
Last updated: December 1, 2011
|
